180
Participants
Start Date
September 16, 2024
Primary Completion Date
June 19, 2029
Study Completion Date
June 19, 2029
RO7567132 and Atezolizumab
RO7567132 will be administered either as monotherapy or in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
RO7567132 and Atezolizumab
RO7567132 will be administered in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
RECRUITING
Kinghorn Cancer Centre, Darlinghurst
RECRUITING
Rigshospitalet, København Ø
RECRUITING
UZ Leuven Gasthuisberg, Leuven
RECRUITING
Austin Health, Heidelberg
RECRUITING
Clinica Universidad de Navarra Madrid, Madrid
RECRUITING
Fundacion Jimenez Diaz, Madrid
RECRUITING
Clinica Universidad de Navarra, Pamplona
RECRUITING
Institut Claudius Regaud, Toulouse
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Centre Leon Berard, Lyon
RECRUITING
Institut Gustave Roussy, Villejuif
RECRUITING
Brown University Health, Providence
RECRUITING
BC Cancer Vancouver, Vancouver
RECRUITING
Princess Margaret Cancer Center, Toronto
RECRUITING
McGill University Health Center, Montreal
RECRUITING
Vall d'Hebron' Institute of Oncology (VHIO), Barcelona, Barcelona
Hoffmann-La Roche
INDUSTRY